Back to top
more

Insulet Corporation (PODD)

(Delayed Data from NSDQ)

$279.69 USD

279.69
257,906

+5.95 (2.17%)

Updated Jul 30, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 27% (184 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

Research for PODD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insulet Corporation [PODD]

Reports for Purchase

Showing records 121 - 140 ( 249 total )

Company: Insulet Corporation

Industry: Medical - Products

Record: 121

04/26/2016

Daily Note

Pages: 15

Diabetes 1Q16 Earnings Preview: Despite Seasonally Soft 1Q, Expecting Healthy Trends Driven By New Product Launches

Provider: Wedbush Securities Inc.

Price: 50.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 122

04/20/2016

Daily Note

Pages: 6

Neulasta Onpro Kit Prescriptions Gain Significant Share in March; Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 123

04/19/2016

Industry Report

Pages: 7

Medical Devices - Takeaways from J-J''s 1Q16 Results

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 124

04/19/2016

Daily Note

Pages: 40

1Q16 MedTech Preview: Stable Trends; Prefer the Oversold Names With Solid Fundamentals

Provider: Wedbush Securities Inc.

Price: 75.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 125

03/24/2016

Daily Note

Pages: 6

Neulasta Onpro Kit Shows a Sequential Decline in February After Very High January Sales Data, But Overall Trend Remains Positive; Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 126

02/26/2016

Company Report

Pages: 8

Pumped about PODD''s Performance in the Quarter and Better Than Expected Guidance; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 127

02/25/2016

Daily Note

Pages: 5

Extremely High Neulasta Onpro Kit Sales Reported in January...An Outlier or the New Reality? Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 128

02/10/2016

Industry Report

Pages: 9

Survey of Diabetes Educators Very Positive for DXCM''s Growth Outlook; Suggests Recent Concerns Misplaced; Reiterate OUTPERFORM on DXCM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 129

01/31/2016

Industry Report

Pages: 11

Proprietary Survey of Diabetes Educators Suggests Patients Prefer Tandem''s Insulin Pumps; Reiterate OUTPERFORM on TNDM shares

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 130

01/20/2016

Daily Note

Pages: 6

Neulasta Onpro Kit Enters 2016 with Solid Momentum and Room to Deliver Potential Upside; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 131

12/23/2015

Daily Note

Pages: 5

Neulasta Onpro Kit Continued to Make Solid Share Gains in November; Now Represents 25% of Neulasta Franchise; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 132

12/17/2015

Industry Report

Pages: 7

Positive (Albeit Temporary) Implications of a 2-Year Suspension of the Medical Device Tax

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 133

11/25/2015

Daily Note

Pages: 5

October Neulasta Onpro Kit Symphony Health Sales Estimate Reflects Continued Solid Share Gains; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 134

11/05/2015

Company Report

Pages: 7

Improving Business Trends Tough To Ignore This Time; Raising PT to $44; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 135

10/29/2015

Daily Note

Pages: 6

Drug Delivery and International Performing Very Well; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 136

10/28/2015

Daily Note

Pages: 5

Ypsomed FY1H16 Results Suggest It Remains On Track To Grow Its OmniPod Installed Base by 40%; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 137

10/21/2015

Daily Note

Pages: 5

Neulasta On-Body Injector Symphony Health Sales Estimate: September Data Suggests A Return to Solid Share Gains; Maintain OUTPERFORM and $40 PT

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 138

10/19/2015

Daily Note

Pages: 45

3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility

Provider: Wedbush Securities Inc.

Price: 100.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 139

10/19/2015

Daily Note

Pages: 45

3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility

Provider: Wedbush Securities Inc.

Price: 100.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 140

09/24/2015

Daily Note

Pages: 6

Neulasta On Body Injector Symphony Health Sales Estimate

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party